Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) FCF Margin: 2017-2025

Historic FCF Margin for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to -341.17%.

  • Autolus Therapeutics' FCF Margin fell 114904.00% to -341.17% in Q3 2025 from the same period last year, while for Sep 2025 it was -557.85%, marking a year-over-year decrease of 99998.00%. This contributed to the annual value of -2,256.38% for FY2024, which is 696464.00% up from last year.
  • Autolus Therapeutics' FCF Margin amounted to -341.17% in Q3 2025, which was up 10.84% from -382.63% recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' FCF Margin ranged from a high of 807.87% in Q3 2024 and a low of -169,124.14% during Q4 2024.
  • In the last 3 years, Autolus Therapeutics' FCF Margin had a median value of -368.97% in 2023 and averaged -15,801.11%.
  • In the last 5 years, Autolus Therapeutics' FCF Margin soared by 1,753,345bps in 2023 and then tumbled by 16,912,904bps in 2024.
  • Over the past 5 years, Autolus Therapeutics' FCF Margin (Quarterly) stood at -630.51% in 2021, then surged by 61,396bps to -16.55% in 2022, then skyrocketed by 2,145bps to 4.90% in 2023, then tumbled by 16,912,904bps to -169,124.14% in 2024, then tumbled by 114,904bps to -341.17% in 2025.
  • Its FCF Margin was -341.17% in Q3 2025, compared to -382.63% in Q2 2025 and -933.07% in Q1 2025.